^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IBI-323

    i
    Other names: IBI-323, IBI323, IBI 323
    Associations

    News

    Trials
    Company:
    Innovent Biologics
    Drug class:
    PD-L1 inhibitor, LAG-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC (clinicaltrials.gov)
    P2, N=70, Recruiting, Hunan Province Tumor Hospital | Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Enrollment open • Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement
    |
    Avastin (bevacizumab) • Alecensa (alectinib) • IBI-323
    over1year
    Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Hunan Province Tumor Hospital | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement
    |
    Avastin (bevacizumab) • Alecensa (alectinib) • IBI-323